Newsletter | January 14, 2021

01.14.21 -- How Biotechs Helped Shape Vibalogics' New Manufacturing Facility

From The Editor

Happy Thursday, Cell & Gene readers,


Vibalogics is building its second manufacturing facility in Boston. CEO Tom Hochuli and president and managing director Dr. Stefan Beyer answer my questions about how biotechs have helped shape their new facility’s capabilities.


Good documentation practices and data integrity (GDP/DI) are inseparable elements of data management, the foundation of any quality system, and are applicable to all departments. Here are some very specific requirements for data capture to follow GDP.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Unprecedented Growth — And Challenges — In Gene Therapy

Gene therapy is a rapidly growing area in healthcare but, now that the promise has been shown, we must focus on improving the manufacturing process and reducing costs.

Why High Purity Of Amino Acids Is The Foundation For Achieving Reliable Media Performance

The primary foundation for reliable media performance remains natural amino acids manufactured at the highest possible standards for quality and purity. As a minimum, amino acids used in biopharma processes must be animal-origin free, governed by strict change control policies, and utilize precisely controlled processes to eliminate impurities such as endotoxins and heavy metals

Optimization Strategy And Process Economics Of DNA Digestion In Viral Vector Production For Gene Therapy

Benzonase endonuclease is a high-quality product delivering immense value to viral vector processes. The enzyme activity is strongly influenced by the matrix and optimization of its use should be a mandatory step in process development. In this application note, we highlight an optimization strategy and process economics of DNA digestion in viral vector purification.

How To Implement Cleanroom Upgrades While Operating Your Facility

It goes without saying that upgrades during a manufacturing shutdown pose less risk as there are no products being produced, but there are instances when it is critical to expand capacity or modify functionality while maintaining some processing. Following are steps to help maintain control of production and changes — and demonstrate proof of control — while keeping the involved workers and the products safe.

Transforming Clinical Development

To enable the completion of clinical trials as safely, efficiently, and quickly as possible, PerkinElmer Informatics’ clinical solutions streamline clinical trial data visualization and analysis with real-time access to clinical data in all phases of clinical development.

Thermo Fisher Scientific Pharma Services Global Network

Our objective is to help speed your molecule through early-phase trials to prepare you for commercial success. This e-book explains our comprehensive support to help streamline the end-to-end process.

Accelerate Your Pipeline With CDMO Collaboration

A growing focus on niche drugs for smaller patient populations has created a tremendous amount of change in the biopharma industry. Investing in a large facility for a single product is no longer a sustainable business model. Instead, pharma companies are looking to collaborate with CDMOs to augment their capacity and expertise, refine their processes, and ultimately shorten their time-to-market. This e-book is designed to help you determine if working with a CDMO is right for you — and if so, you’ll discover the best practices that make working with a CDMO as efficient as possible.

Depot-To-Patient Service Overview

This infographic provides an overview of Fisher Clinical’s depot-to-patient solution to support decentralized clinical trials in the U.S.